Codexis Announces New Employment Inducement Grants
Codexis (NASDAQ: CDXS) has announced the approval of equity grants for two new employees, as authorized by the company's Compensation Committee. The inducement awards, granted under the 2024 Inducement Plan, include:
Stock Options: 23,000 shares with an exercise price matching Codexis' Nasdaq closing price on grant date. These vest over 4 years, with 25% vesting after year one and the remainder vesting monthly.
Restricted Stock Units (RSUs): 11,500 units vesting in equal annual installments over three years from the grant date.
Both awards are subject to continued employment with Codexis through applicable vesting dates. This disclosure complies with Nasdaq Listing Rule 5635(c)4.
Codexis (NASDAQ: CDXS) ha annunciato l'approvazione di concessioni azionarie per due nuovi dipendenti, come autorizzato dal Comitato Compensi dell'azienda. I premi di indennità, concessi nell'ambito del Piano di Indennità 2024, includono:
Opzioni su azioni: 23.000 azioni con un prezzo di esercizio pari al prezzo di chiusura di Codexis su Nasdaq nella data di concessione. Queste si maturano in 4 anni, con il 25% che si matura dopo il primo anno e il restante che si matura mensilmente.
Unità azionarie vincolate (RSU): 11.500 unità che maturano in rate annuali uguali per tre anni dalla data di concessione.
Entrambi i premi sono soggetti a continua occupazione con Codexis fino alle date di maturazione applicabili. Questa comunicazione è conforme alla Regola di Quotazione Nasdaq 5635(c)4.
Codexis (NASDAQ: CDXS) ha anunciado la aprobación de concesiones de acciones para dos nuevos empleados, tal como lo autorizó el Comité de Compensación de la empresa. Las recompensas por inducimiento, otorgadas bajo el Plan de Inducimiento 2024, incluyen:
Opciones sobre acciones: 23,000 acciones con un precio de ejercicio que coincide con el precio de cierre de Codexis en Nasdaq en la fecha de concesión. Estas se adquieren a lo largo de 4 años, con un 25% adquiriéndose después del primer año y el resto mensual.
Unidades de acciones restringidas (RSUs): 11,500 unidades que se adquieren en plazos anuales iguales durante tres años a partir de la fecha de concesión.
Ambas recompensas están sujetas a la continuidad del empleo con Codexis hasta las fechas de adquisición correspondientes. Esta divulgación cumple con la Regla de Cotización Nasdaq 5635(c)4.
Codexis (NASDAQ: CDXS)는 회사의 보상위원회가 승인한 두 명의 신규 직원에 대한 주식 보상을 발표했습니다. 2024 유도 계획에 따라 부여된 유도 상은 다음과 같습니다:
주식 옵션: 부여일 기준 Codexis의 나스닥 종가와 동일한 행사가격으로 23,000주입니다. 이는 4년에 걸쳐 25%가 1년 후에 배포되고 나머지는 매월 배포됩니다.
제한 주식 단위(RSU): 부여일로부터 3년 동안 매년 동일한 비율로 배포되는 11,500단위입니다.
두 상은 해당 배포 날짜까지 Codexis와의 고용 지속에 따라 달라집니다. 이 공시는 나스닥 상장 규칙 5635(c)4에 부합합니다.
Codexis (NASDAQ: CDXS) a annoncé l'approbation de concessions d'actions pour deux nouveaux employés, tel qu'autorisé par le Comité de Rémunération de l'entreprise. Les récompenses d'incitation, accordées dans le cadre du Plan d'Induction 2024, comprennent :
Options d'actions : 23 000 actions avec un prix d'exercice correspondant au cours de clôture de Codexis sur Nasdaq à la date de concession. Celles-ci se consolident sur 4 ans, avec 25 % de la première année et le reste se consolidant mensuellement.
Unités d'actions restreintes (RSUs) : 11 500 unités se consolidant par versements annuels égaux sur trois ans à partir de la date de concession.
Les deux récompenses sont soumises à un emploi continu chez Codexis jusqu'aux dates de consolidation applicables. Cette divulgation est conforme à la Règle d'inscription Nasdaq 5635(c)4.
Codexis (NASDAQ: CDXS) hat die Genehmigung von Aktienvergaben für zwei neue Mitarbeiter bekannt gegeben, die vom Vergütungsausschuss des Unternehmens genehmigt wurden. Die Anreizvergaben, die im Rahmen des Anreizplans 2024 gewährt wurden, umfassen:
Aktienoptionen: 23.000 Aktien mit einem Ausübungspreis, der dem Schlusskurs von Codexis an der Nasdaq am Vergabetag entspricht. Diese werden über 4 Jahre aufgeschlüsselt, wobei 25% nach dem ersten Jahr und der Rest monatlich fällig wird.
Restricted Stock Units (RSUs): 11.500 Einheiten, die in gleichen jährlichen Raten über einen Zeitraum von drei Jahren ab dem Vergabetag fällig werden.
Beide Vergaben sind an eine fortgesetzte Anstellung bei Codexis bis zu den jeweiligen Fälligkeitsdaten gebunden. Diese Offenlegung entspricht der Nasdaq-Listing-Regel 5635(c)4.
- Implementation of employee retention strategy through equity compensation
- Structured vesting schedule promotes long-term employee commitment
- Potential shareholder dilution from new equity grants
REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 23,000 shares of Codexis common stock and (ii) 11,500 restricted stock units (RSUs) as inducement awards under the Company’s 2024 Inducement Plan.
The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with Codexis through the applicable vesting dates.
Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
How many shares of stock options did Codexis (CDXS) grant in January 2024?
What is the vesting schedule for Codexis (CDXS) 2024 stock option grants?
How many RSUs did Codexis (CDXS) award in January 2024?
What is the vesting schedule for Codexis (CDXS) 2024 RSU grants?
